Praluent
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Praluent (alirocumab; Sanofi/Regeneron) is a fully human monoclonal antibody that inhibits PCSK9 and is intended for the treatment of hypercholesterolemia. PCSK9 is a protease involved in the intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. It binds to the epidermal growth factor-like repeat A domain of the LDLR and targets the receptor for lysosomal degradation within hepatocytes. PCSK9 is also known to increase the production of apolipoprotein B-containing lipoproteins. Praluent prevents circulating PCSK9 from binding to LDLRs, consequently inhibiting degradation. This allows the receptors to be recycled to the surface of hepatocytes, thus increasing plasma clearance of LDL-C.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Praluent : Dyslipidemia
LIST OF FIGURES
9 Figure 1: LDL-C lowering in pivotal trials of PCSK9 inhibitors Repatha and Praluent
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Praluent for dyslipidemia
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Praluent for dyslipidemia
18 Figure 4: Praluent sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2018–27
LIST OF TABLES
6 Table 1: Recent high-impact events for Praluent in dyslipidemia
7 Table 2: Praluent drug profile
8 Table 3: Approval history of Praluent for dyslipidemia in the US, Japan, and five major EU markets
9 Table 4: PCSK9 inhibitors, Repatha and Praluent, cardiovascular outcomes (hazard ratios vs placebo)
10 Table 5: Clinical trials for Praluent in dyslipidemia
13 Table 6: Praluent for dyslipidemia – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Juxtapid 
Sign up to the